nidНефрология и диализNephrology and Dialysis1680-44222618-9801Российское диализное обществоnid-3177Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESНарушение фосфорно-кальциевого обмена у больных хронической почечной недостаточностьюРhosphorus-Сalcium disorders in patients with chronic renal failureМаиОтсMaiOtsmaiots@klinkkum.eeГалинаЗемцовскаяGalinaZemtsovskaianoemail@neicon.ruКлиника внутренних болезней, Тартуский университет, ЭстонияRussian Federation20022806202543182185Copyright © Маи О., Галина З., 20252025Маи О., Галина З.Mai O., Galina Z.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephro.ru/jour/article/view/3177

Введение В течение последних лет нарастает количество исследований, подчеркивающих важность качества жизни больных хронической почечной недостаточностью (ХПН). Несколько десятилетий назад считали, что достаточно просто сохранить жизнь больному. Сегодня мы все осознаем, что наши усилия могут оказаться ничего не стоящими, если жизнь больного не будет полноценной и значимой. Это касается не только пациентов, находящихся на почечной заместительной терапии, но также больных в преддиализной фазе. Поэтому врачу необходимо четко разбираться в механизмах действий, возможностях и ограничениях различных препаратов, а также в методах, используемых при лечении больных на разных стадиях ХПН.

хроническая почечная недостаточностьфосфорно-кальциевый обменренальная остеодистрофиягиперпаратиреозлечениеReferencesНовиков А.И. Способы коррекции гиперфосфатемии при хронической почечной недостаточности и при лечении диализом. Терапевтический архив 1997; 12; 63-67.Новиков А.И. Способы коррекции гиперфосфатемии при хронической почечной недостаточности и при лечении диализом. Терапевтический архив 1997; 12; 63-67.Тануйлова О. Лечение уремической гиперфосфатемии. Русский медицинский журнал 1997.Тануйлова О. Лечение уремической гиперфосфатемии. Русский медицинский журнал 1997.Тануйлова О. Влияние орального приема 1-α гидрокальциферола на плотность костной ткани у больных, находящихся на гемодиализе. Русский медицинский журнал 1997.Тануйлова О. Влияние орального приема 1-α гидрокальциферола на плотность костной ткани у больных, находящихся на гемодиализе. Русский медицинский журнал 1997.Тареева И.Е. Механизмы прогрессирования гломерулонефрита. Терапевтический архив 1996; 6: 5-10.Тареева И.Е. Механизмы прогрессирования гломерулонефрита. Терапевтический архив 1996; 6: 5-10.Chertow G.M., Dillon M., Burke S.K. et al. A randomized trial of sevelamer hydrochlorid (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemaodialysis patients. Clinical Nephrology 1999; 51 (1): 18-26.Chertow G.M., Dillon M., Burke S.K. et al. A randomized trial of sevelamer hydrochlorid (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemaodialysis patients. Clinical Nephrology 1999; 51 (1): 18-26.Foumier A., Fardellone P., Achard J.M. et al. Importance of vitamin D repletion in uremia. Nephrol Dial Transplant 1999; 14: 819-823.Foumier A., Fardellone P., Achard J.M. et al. Importance of vitamin D repletion in uremia. Nephrol Dial Transplant 1999; 14: 819-823.Rostrand S.G., Drueke Т.В. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999; 56: 383-392.Rostrand S.G., Drueke Т.В. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999; 56: 383-392.Block G.A., Hulbert-Shearon Т.Е., Levin N.W. et al. Association of serum phosphorus and calcium phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617.Block G.A., Hulbert-Shearon Т.Е., Levin N.W. et al. Association of serum phosphorus and calcium phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617.New Vitamin D Analogues in the Treatment of Secondary Hyperparathyroidism. Am J Kidney Dis 1998; Supplement 2: 32.New Vitamin D Analogues in the Treatment of Secondary Hyperparathyroidism. Am J Kidney Dis 1998; Supplement 2: 32.Mucsi I., Hercz G., Uldall R. et al. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 1998 May; 53 (5): 1399-1404.Mucsi I., Hercz G., Uldall R. et al. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 1998 May; 53 (5): 1399-1404.Llach F., Yudd M. The importance of hyperphosphatemia in the severity of hyperparathyroidism and its treatment in patients with chronic renal failure. Nephrol Dial Transplant 1998; 13: 57-61.Llach F., Yudd M. The importance of hyperphosphatemia in the severity of hyperparathyroidism and its treatment in patients with chronic renal failure. Nephrol Dial Transplant 1998; 13: 57-61.Llach F. (Editorials) Calcific Uremic Arteriolopathy (Calciphylaxis): An Evolving Entity? Am J Kidnev Dis 1998; 32: 514-518.Llach F. (Editorials) Calcific Uremic Arteriolopathy (Calciphylaxis): An Evolving Entity? Am J Kidnev Dis 1998; 32: 514-518.Slatopolsky E.A. The role of calcium, phosphorus and vitamin D metabolism in the development of secondary hyperparathyroidism. Nephrol Dial Transplant 1998; 12: 3-8.Slatopolsky E.A. The role of calcium, phosphorus and vitamin D metabolism in the development of secondary hyperparathyroidism. Nephrol Dial Transplant 1998; 12: 3-8.Ribero S., Ramos A., Brandao A. et al. Cardiac valves calcification in hemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant 1998; 13: 2037-2040.Ribero S., Ramos A., Brandao A. et al. Cardiac valves calcification in hemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant 1998; 13: 2037-2040.Goldberg D.I., Dillon M.A., Slatopolsky E.A. et al. Effect of RenaGel®, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 1998; 13: 2303-2310.Goldberg D.I., Dillon M.A., Slatopolsky E.A. et al. Effect of RenaGel®, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 1998; 13: 2303-2310.Messa P., Gropuzzo M., Cleva M. et al. Behavior of phosphate removal with different dialysis schedules. Nephrol Dial Transplant 1998; 13 (Suppl 6): 43-48.Messa P., Gropuzzo M., Cleva M. et al. Behavior of phosphate removal with different dialysis schedules. Nephrol Dial Transplant 1998; 13 (Suppl 6): 43-48.Burke S.K., Slatopolsky E.A., Goldberg D.I. RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant 1997; 12: 640-644.Burke S.K., Slatopolsky E.A., Goldberg D.I. RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant 1997; 12: 640-644.Chertow G.M., Burke S.K., Lazarus J.M. et al. Poly [allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997; 29: 66-71.Chertow G.M., Burke S.K., Lazarus J.M. et al. Poly [allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997; 29: 66-71.Denda M., Finch J., Slatopolsky E. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis 1996; 28 (4): 596-602.Denda M., Finch J., Slatopolsky E. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis 1996; 28 (4): 596-602.Drueke Т.В. A clinical approach to the uraemic patient with extrasceletal calcifications. Nephrol Dial Transplant 1996; 11: 37-42.Drueke Т.В. A clinical approach to the uraemic patient with extrasceletal calcifications. Nephrol Dial Transplant 1996; 11: 37-42.Llach F., Bover J. Renal osteodystrophy in Brenner and Rector’s The Kidney 1996; 2187-2273; ed. By Brenner BM.Llach F., Bover J. Renal osteodystrophy in Brenner and Rector’s The Kidney 1996; 2187-2273; ed. By Brenner BM.Femandez E., Montoliu J. Successful treatment of massive uraemic tumoral calcinosis with daily hemodialysis and very low calcium dialysate. Nephrol Dial Tranplant 1994; 9 (8): 1207-1209.Femandez E., Montoliu J. Successful treatment of massive uraemic tumoral calcinosis with daily hemodialysis and very low calcium dialysate. Nephrol Dial Tranplant 1994; 9 (8): 1207-1209.Slatopolsky E.A., Delmez J.A. Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 1994; 23: 229-236.Slatopolsky E.A., Delmez J.A. Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 1994; 23: 229-236.Lopez-Hilker S., Dusso A.S., Rapp N.S. et al. Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am J Physiol 1990; 259: 432-437.Lopez-Hilker S., Dusso A.S., Rapp N.S. et al. Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am J Physiol 1990; 259: 432-437.Szabo A., Merke J., Beier E., Mall G., Ritz E. 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989; 35: 1049-1056.Szabo A., Merke J., Beier E., Mall G., Ritz E. 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989; 35: 1049-1056.Maher E.R., Young G., Smyth-Walsh B. et al. Aortic and mitral valve calcification in patient with ESRD. Lancet 1987; 2: 875-877.Maher E.R., Young G., Smyth-Walsh B. et al. Aortic and mitral valve calcification in patient with ESRD. Lancet 1987; 2: 875-877.Gipstein R.M., Coburn J.W., Adams D.A. et al. Calciphylaxis in man. Arch Int Med 1976; 136: 1273-1280.Gipstein R.M., Coburn J.W., Adams D.A. et al. Calciphylaxis in man. Arch Int Med 1976; 136: 1273-1280.

The authors declare that there are no conflicts of interest present.